Loading...
LUMRYZ Launch Will Fuel Long-Term Orphan Drug Market Growth
AN
AnalystHighTarget
Not Invested
Consensus Narrative from 8 Analysts
Published
26 Aug 25
Updated
26 Aug 25
AnalystHighTarget's Fair Value
US$24.00
38.0% undervalued intrinsic discount26 Aug
US$14.87
1Y
-0.1%7D
0.3%1Y
-0.1%7D
0.3%